Search results for "fusions"

showing 10 items of 176 documents

Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with…

2002

Irinotecan (CPT-11), oxaliplatin (OXA) and different folinic acid (FA) modulated 5-fluorouracil (5-FU) regimens are active as first-and second-line chemotherapy of metastatic colorectal cancer. However, the best palliative sequence of these substances is still unclear. After CPT-11 containing regimens the optimal salvage protocol has not yet been defined. Here, we retrospectively analysed the weekly ambulant combination of OXA with continuous FA/5-FU (FUFOX) after two different CPT-11 containing chemotherapeutic regimens. Patients: During October 1999 and May 2001, 20 patients (median 62; 48-74 years) were included who had disease progression after CPT-11/bolus FA/5-FU (Saltz; 7 patients, g…

Malemedicine.medical_specialtyAntimetabolites AntineoplasticPalliative careTime FactorsOrganoplatinum Compoundsmedicine.medical_treatmentLeucovorinSalvage therapyAntineoplastic AgentsIrinotecanGastroenterologyFolinic acidInternal medicineMucositisMedicineHumansNeoplasm MetastasisInfusions IntravenousAgedRetrospective StudiesSalvage TherapyChemotherapybusiness.industryPalliative CareGastroenterologyMiddle Agedmedicine.diseaseAntineoplastic Agents PhytogenicOxaliplatinSurgeryIrinotecanOxaliplatinFluorouracilCamptothecinFemaleFluorouracilbusinessColorectal Neoplasmsmedicine.drugZeitschrift fur Gastroenterologie
researchProduct

Nitric oxide mediates the inhibition by interleukin-1β of pentagastrin-stimulated rat gastric acid secretion

1993

Bolus injection of interleukin-1 beta (2 micrograms kg-1, i.v.) inhibited acid secretion induced by intravenous infusion of pentagastrin (8 micrograms kg-1 h-1) in the continuously perfused stomach of the anaesthetized rat. Administration of interleukin-1 beta did not modify mean systemic arterial blood pressure. Pretreatment with NG-nitro-L-arginine methyl ester (L-NAME, 2-10 mg kg-1, i.v.), but not dexamethasone (5 mg kg-1, s.c. twice over 16 h), restored the acid secretory responses to pentagastrin. The actions of L-NAME were reversed by the prior administration of L-arginine (100 mg kg-1, i.v.), but not by its enantiomer D-arginine (100 mg kg-1, i.v.). L-NAME (5 mg kg-1, i.v.) increased…

Malemedicine.medical_specialtyBlood PressureBiologyPeptide hormoneArginineNitric OxideNitric oxideGastric Acidchemistry.chemical_compoundInternal medicinemedicineAnimalsRats WistarInfusions IntravenousPhenylephrineDexamethasonePharmacologyStomachStereoisomerismRatsPentagastrinNG-Nitroarginine Methyl Estermedicine.anatomical_structureEndocrinologychemistryGastrointestinal hormoneGastric acidFemalePentagastrinResearch ArticleInterleukin-1medicine.drugBritish Journal of Pharmacology
researchProduct

The use of zoledronic acid in patients with bone metastases from prostate carcinoma: Effect on analgesic response and bone metabolism biomarkers

2005

Zoledronic acid is a bisphosphonate that is effective in the treatment of complications of metastatic bone disease. We have carried out a perspective study on 24 consecutive patients with prostate cancer metastatic to bone to verify the effect of zoledronic acid on analgesic response and a possible relationship with the levels of bone metabolism biomarkers. Eligibility for this study required prostate cancer patients with metastatic bone disease and pain not controlled by analgesics. Patients were excluded from the study if they were receiving cytotoxic chemotherapy or radiation therapy within three months. Eighteen patients (75%) were considered responder to acid zoledronic, only 6 patient…

Malemedicine.medical_specialtyBone diseasemedicine.medical_treatmentPainBone NeoplasmsGastroenterologyBone resorptionBone remodelingProstate cancerzoledronic acidInternal medicinemedicineHumansPharmacology (medical)Bone ResorptionInfusions Intravenousbone metastaseAgedPain MeasurementPharmacologyBone Density Conservation AgentsDiphosphonatesbusiness.industryImidazolesProstatic NeoplasmsMiddle AgedBisphosphonatemedicine.diseaseprostate cancerSurgeryRadiation therapyBone Density Conservation AgentsInfectious DiseasesZoledronic acidOncologybone metabolism biomarkerbusinessBiomarkersmedicine.drug
researchProduct

Nitric oxide and prostacyclin lower suprasystemic pulmonary hypertension after cardiopulmonary bypass

1993

In a 3-week-old male newborn persistent suprasystemic pulmonary hypertension developed after surgical valvulotomy for a critical aortic valve stenosis. Because of a residual transvalvular pressure gradient of 35 mmHg and postoperative left as well as right ventricular dysfunction, treatment with inhaled nitric oxide (NO) and intravenously infused prostacyclin (PGI2) was attempted. Low-dose inhaled NO and low dose PGI2 corrected severe pulmonary hypertension and led to an increase in cardiac output. Treatment with NO but not PGI2 was accompanied by a rise in PaO2 and systemic blood pressure. Interruption of NO administration led to a rapid increase in pulmonary arterial pressure to suprasyst…

Malemedicine.medical_specialtyCardiac outputHypertension Pulmonarymedicine.medical_treatmentBlood PressureNitric OxidePostoperative ComplicationsInternal medicineHypoxic pulmonary vasoconstrictionAdministration InhalationmedicineHumansEndothelial dysfunctionInfusions IntravenousPulmonary wedge pressureCardiopulmonary Bypassbusiness.industryHemodynamicsInfant NewbornAortic Valve Stenosismedicine.diseaseEpoprostenolPulmonary hypertensionValvulotomyBlood pressureAnesthesiaAortic valve stenosisPediatrics Perinatology and Child Healthcardiovascular systemCardiologyDrug Therapy CombinationbusinessEuropean Journal of Pediatrics
researchProduct

Novel antihypertensive hexa- and heptapeptides with ACE-inhibiting properties: From the in vitro ACE assay to the spontaneously hypertensive rat

2011

Bioactive ACE inhibiting peptides are gaining interest in hypertension treatment. We have designed and screened six synthetic heptapeptides (PACEI48 to PACEI53) based on two hexapeptide leads (PACEI32 and PACEI34) to improve ACE inhibitory properties and assess their antihypertensive effects. ACE activity was assayed in vitro and ex vivo. Selected peptides were administered to spontaneously hypertensive rats (SHRs) and normotensive Wistar-Kyoto (WKY) rats. In vitro cytotoxicity was assessed with the MTT reduction test. The six heptapeptides at low micromolar concentration produced different degrees of in vitro inhibition of ACE activity using the synthetic substrate HHL or the natural subst…

Malemedicine.medical_specialtyCell SurvivalPhysiologyAdministration OralAngiotensin-Converting Enzyme InhibitorsBlood PressurePeptidyl-Dipeptidase APharmacologyRats Inbred WKYBiochemistryTissue Culture TechniquesMiceCellular and Molecular NeuroscienceEndocrinologySpontaneously hypertensive ratOral administrationRats Inbred SHRInternal medicineRenin–angiotensin systemmedicineAnimalsHumansInfusions IntravenousAntihypertensive AgentsbiologyChemistryAngiotensin-converting enzyme3T3 CellsHep G2 CellsIn vitroRatsCarotid ArteriesEndocrinologyVasoconstrictionHypertensionACE inhibitorbiology.proteinRabbitsAngiotensin Imedicine.symptomOligopeptidesVasoconstrictionEx vivomedicine.drug
researchProduct

Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refr…

2000

Background: Diuretics, have been accepted as first-line treatment in refractory heart failure, but a lack of response is a frequent event. A randomised single blind study was performed to evaluate the effects of the combination of high-dose furosemide and small-volume hypertonic saline solution (HSS) infusion in the treatment of refractory NYHA class IV congestive heart failure (CHF). Materials and methods: Sixty patients (21 F/39 M) with refractory CHF (NYHA class IV) of different etiologies, unresponsive to high oral doses of furosemide, ACE-inhibitors, digitalis, and nitrates, aged 65–90 years, were enrolled. They had to have an ejection fraction (EF) < 35%, serum creatinine < 2 mg/dl, B…

Malemedicine.medical_specialtyDiuresisBlood PressurePotassium Chloridechemistry.chemical_compoundBolus (medicine)FurosemideHeart RateHumansMedicineSingle-Blind MethodDiureticsInfusions IntravenousAgedAged 80 and overHeart FailureSaline Solution HypertonicCreatinineEjection fractionbusiness.industryBody WeightSodiumFurosemideMiddle Agedmedicine.diseaseHypokalemiaDiuresisUric AcidSurgerychemistryCreatinineAnesthesiaHeart failurePotassiumDrug Therapy CombinationFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessHyponatremiamedicine.drugEuropean Journal of Heart Failure
researchProduct

The treatment of venous leg ulcers: a new therapeutic use of iloprost

2007

Background: We conducted a study using an intravenous (i.v.) infusion of iloprost in the treatment of venous ulcers to verify whether the association of i.v. iloprost + local therapy + elastic compression has a favorable effect when compared with traditional treatment with local therapy and elastic compression. Study Design: We evaluated the effects of iloprost in 98 consecutive patients with noncomplicated venous ulcers of lower limbs subdivided into 2 groups: the first group (48 patients) received iloprost in saline solution for 3 weeks and the second group (50 patients) received a venous infusion of a saline solution. The patients were examined at baseline time 0 (first visit) and then a…

Malemedicine.medical_specialtyElastic compressionmedicine.medical_treatmentIschemiaPlacebo groupDrug Administration Schedulelaw.inventionRandomized controlled triallawmedicineHumansSingle-Blind MethodIloprostInfusions IntravenousVeinSalineDose-Response Relationship Drugbusiness.industryvenous ulcersiloprostLeg UlcerSignificant differenceMiddle Agedmedicine.diseaseCombined Modality TherapySurgeryTreatment Outcomemedicine.anatomical_structureDebridementAnesthesiaAnti-Infective Agents LocalFemaleSurgeryVENOUS LEG ULCERS ILOPROSTbusinessPlatelet Aggregation InhibitorsStockings CompressionIloprostmedicine.drug
researchProduct

Fabry disease: enzyme replacement therapy

2003

Fabry disease is a multisystem disorder associated with wide variability in clinical expression. Fabry disease is an X-linked lysosomal storage disorder caused by a deficiency of alpha-galactosidase A. The enzyme defect leads to the systemic accumulation of glycosphingolipids with alpha-galactosyl moieties consisting predominantly of globotriaosylceramide, galabiosylceramide and two additional glycosphingolipids. Four hemizygotes patients with a family history of Fabry disease and deficiency of the enzyme alpha-galactosidase A were selected. Each patient received purified alpha-galactosidase by intravenous infusion (0.2 mg/kg). The infusion was administered every 2 weeks, for 40 min, for a …

Malemedicine.medical_specialtyGlobotriaosylceramideRenal functionVasomotionCorneal dystrophyDermatologyRisk AssessmentGastroenterologyDrug Administration ScheduleSampling Studieschemistry.chemical_compoundInternal medicineHumansMedicineFamily historyInfusions IntravenousDose-Response Relationship Drugbusiness.industryBiopsy NeedleOutcome measuresEnzyme replacement therapymedicine.diseaseImmunohistochemistryFabry diseaseTreatment OutcomeInfectious DiseasesEndocrinologychemistryalpha-GalactosidaseFabry DiseaseFemalebusinessFollow-Up StudiesJournal of the European Academy of Dermatology and Venereology
researchProduct

Short-Term Effects of Hypertonic Saline Solution in Acute Heart Failure and Long-Term Effects of a Moderate Sodium Restriction in Patients With Compe…

2011

INTRODUCTION: Hypertonic saline solution (HSS) and a moderate Na restriction plus high furosemide dose showed beneficial effects in compensated heart failure (HF), in short and long terms. The study was aimed to verify the effects of this combination on hospitalization time, readmissions and mortality in patients in New York Heart Association (NYHA) class III. METHOD: Chronic ischemic or nonischemic cardiomyopathy uncompensated patients with HF in NYHA III functional class with ejection fraction <40%, serum creatinine <2.5 mg/dL, blood urea nitrogen <60 mg/dL and reduced urinary volume were single-blind randomized in 2 groups: the first group received a 30-minute intravenous infusion of fur…

Malemedicine.medical_specialtyHeart diseasemedicine.medical_treatmentDiuresisPatient ReadmissionFurosemideInternal medicinemedicineHumansInfusions IntravenousAgedAged 80 and overHeart FailureSaline Solution HypertonicEjection fractionbusiness.industrySodiumFurosemideGeneral MedicineDiet Sodium-RestrictedMiddle Agedmedicine.diseaseHyepertonic saline heart failure diureticsDiuresisSurgeryHospitalizationTreatment OutcomeHeart failureCirculatory systemCardiologyTonicityFemaleDiureticbusinessmedicine.drugThe American Journal of the Medical Sciences
researchProduct

Hypertonic saline solution and decompressive craniectomy for treatment of intracranial hypertension in pediatric severe traumatic brain injury.

2002

Experimental data 8 –11 and first clinical results in adults 12,13 suggest that hypertonic saline ( 1.0) may be highly effective in lowering ICP even when mannitol has lost its therapeutic potential after prolonged and repeated use. In children, only limited experience exists with the use of hypertonic saline solutions: a randomized prospective study in children with severe head injury compared the effects on ICP (increased to 15–20 mm Hg) of isotonic (0.9% NaCl) and hypertonic (3% NaCl) saline injections, demonstrating a beneficial effect of the hypertonic solution. 14 Another prospective randomized trial compared the effects of continuous infusion of either lactated Ringer’s solution (277…

Malemedicine.medical_specialtyIntracranial PressureTraumatic brain injurymedicine.medical_treatmentBrain damageCritical Care and Intensive Care MedicineDrug Administration ScheduleInjury Severity ScorePreoperative CaremedicineHumansChildInfusions IntravenousSalineOsmolePostoperative CareSaline Solution Hypertonicbusiness.industryHead injurySodiumGlasgow Coma ScaleAccidents Trafficmedicine.diseaseDecompression SurgicalHypertonic salineSurgeryAnesthesiaBrain InjuriesSurgeryDecompressive craniectomyAccidental Fallsmedicine.symptomIntracranial HypertensionbusinessTomography X-Ray ComputedCraniotomyThe Journal of trauma
researchProduct